Verastem
VSTM | NASDAQ
$7.70
-$0.48 (-5.87%)
At close: Nov 16, 2026, 4:00 PM ET
$7.78
+$0.08 (+1.04%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Verastem Company Profile
Company profile explainedCompany Profile
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Daniel W. Paterson | President, Chief Executive Officer & Director |
| Daniel Calkins | Chief Financial Officer |
| Cathy Carew | Chief Organizational Effectiveness Officer |
| Jonathan Pachter | Chief Scientific Officer |
| Julissa Viana | Vice President of Corporate Communications & Investor Relations |
| Lori Horvat | Executive Vice President of Portfolio Strategy & Operations |
| Mark J. Wanda | Senior VP of Legal & Chief Compliance Officer |
| Michael Glen Kauffman | President of Development & Director |
| Michelle Detwiler | Co-Founder |
| Nathan Sanburn | Chief Business Officer |
| Robert A. Weinberg | Co-Founder & Chair of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 14, 2026 | 8-K | Current Report |
| Oct 14, 2026 | 424B5 | Filing |
| Oct 14, 2026 | 424B5 | Filing |
| Oct 14, 2026 | 8-K | Current Report |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Sep 23, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
Verastem
| Country | United States |
| IPO Date | Jan 27, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Daniel W. Paterson |
Contact Details
117 Kendrick Street Needham,
Massachusetts 02494 United States
Stock Details
| Ticker Symbol | VSTM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001526119 |
| CUSIP Number | 92337C203 |
| ISIN Number | US92337C2035 |
| SIC Code | 2834 |
Recent News
- 11 hours ago / marketbeat.comVerastem Weighs Partnership or Solo Launch as Cancer Drug Trials Advance
- 5 days ago / marketbeat.comVerastem Bets on Higher Cancer Drug Dose as It Maps Potential Approval Path
- 6 days ago / marketbeat.comVerastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial Plans
- 10 days ago / marketbeat.comWhat Verastem (VSTM) Said on Its Q3 Earnings Call
Add to Watchlist
Select watchlists to add or remove VSTM